Apolipoprotein B and non-HDL cholesterol are more powerful predictors for incident type 2 diabetes than fasting glucose or glycated hemoglobin in subjects with normal glucose tolerance: a 3.3-year retrospective longitudinal study

Acta Diabetologica

Volumn 51, Issue 6, 2014, Pages 941-946

  Hwang, You Cheol ^a   Ahn, Hong Yup ^b   Park, Sung Woo ^c   Park, Cheol Young ^c  

^a Kyung Hee University College of Medicine   (South Korea)

^b Dongguk University   (South Korea)

^c School of Medicine   (South Korea)

Author keywords

Apolipoprotein B; Non HDL cholesterol; Normal glucose tolerance; Type 2 diabetes

Indexed keywords

APOLIPOPROTEIN B; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; CHOLESTEROL; GLUCOSE BLOOD LEVEL; HEMOGLOBIN A1C PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; ATHEROGENIC DYSLIPIDEMIA; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DYSLIPIDEMIA; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HUMAN; INCIDENCE; INSULIN SENSITIVITY; LIPOPROTEIN BLOOD LEVEL; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; ANALYSIS; BLOOD; DIABETES MELLITUS, TYPE 2; DIET RESTRICTION; METABOLISM; MIDDLE AGED; PREDICTIVE VALUE; PROGNOSIS; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; APOLIPOPROTEINS B; BLOOD GLUCOSE; CHOLESTEROL; DIABETES MELLITUS, TYPE 2; FASTING; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INCIDENCE; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84919448323     PISSN: 09405429     EISSN: 14325233     Source Type: Journal    
DOI: 10.1007/s00592-014-0587-x     Document Type: Article

References (19)

1. Adiels M, Olofsson SO, Taskinen MR, Borén J (2008) Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome. Arterioscler Thromb Vasc Biol 28:1225–1236
2. Bamba V, Rader DJ (2007) Obesity and atherogenic dyslipidemia. Gastroenterology 132:2181–2190
3. Barter PJ (2011) The causes and consequences of low levels of high-density lipoproteins in patients with diabetes. Diabetes Metab J 35:101–106
4. Sniderman AD, Furberg CD, Keech A et al (2003) Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment. Lancet 361:777–780
5. Kastelein JJ, van der Steeg WA, Holme I et al (2008) Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment. Circulation 117:3002–3009
6. Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E (2001) High apolipoprotein B, low apolipoprotein A-I and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 358:2026–2033
7. Thompson A, Danesh J (2006) Associations between apolipoprotein B, apolipoprotein AI, the apolipoprotein B/AI ratio and coronary heart disease: a literature-based meta-analysis of prospective studies. J Intern Med 259:481–492
8. Ley SH, Harris SB, Connelly PW et al (2010) Association of apolipoprotein B with incident type 2 diabetes in an aboriginal Canadian population. Clin Chem 56:666–670
9. Salomaa V, Havulinna A, Saarela O et al (2010) Thirty-one novel biomarkers as predictors for clinically incident diabetes. PLoS ONE 5:e10100
10. Hwang YC, Ahn HY, Yu SH, Park SW, Park CY (2014) Atherogenic dyslipidaemic profiles associated with the development of Type 2 diabetes: a 3.1-year longitudinal study. Diabet Med 31:24–30
11. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (2001) Executive summary of the third report of the national cholesterol education program (NCEP) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285:2486–2497
12. American Diabetes Association (2010) Diagnosis and classification of diabetes mellitus. Diabetes Care 33:S62–S69
13. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–419
14. Binnert C, Genoud M, Seematter G et al (2005) Glucose-induced insulin secretion in dyslipidemic and normolipidemic patients with normal glucose tolerance. Diabetes Care 28:1225–1227
15. Laakso M, Sarlund H, Mykkänen L (1990) Insulin resistance is associated with lipid and lipoprotein abnormalities in subjects with varying degrees of glucose tolerance. Arteriosclerosis 10:223–231
16. Chahil TJ, Ginsberg HN (2006) Diabetic dyslipidemia. Endocrinol Metab Clin North Am 35:491–510
17. Samuel VT, Petersen KF, Shulman GI (2010) Lipid-induced insulin resistance: unravelling the mechanism. Lancet 375:2267–2277
18. Meigs JB, Nathan DM, Wilson PW, Cupples LA, Singer DE (1998) Metabolic risk factors worsen continuously across the spectrum of nondiabetic glucose tolerance. The Framingham Offspring Study. Ann Intern Med 128:524–533
19. Preiss D, Seshasai SR, Welsh P et al (2011) Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA 305:2556–2564